A Systematic Review of Cost-Effectiveness Studies of Newer Non-Insulin Antidiabetic Drugs: Trends in Decision-Analytical Models for Modelling of Type 2 Diabetes Mellitus-Reference-Cited by-同舟云学术

A Systematic Review of Cost-Effectiveness Studies of Newer Non-Insulin Antidiabetic Drugs: Trends in Decision-Analytical Models for Modelling of Type 2 Diabetes Mellitus

Published:2023-07-06 Issue:11 Volume:41 Page:1469-1514
ISSN:1170-7690
Container-title:PharmacoEconomics
language:en
Short-container-title:PharmacoEconomics

Author:

Laursen Henrik Vitus Bering^ORCID,Jørgensen Emmelie Ploug,Vestergaard Peter^ORCID,Ehlers Lars Holger^ORCID

Publisher

Springer Science and Business Media LLC

Subject

Public Health, Environmental and Occupational Health,Health Policy,Pharmacology

Link

https://link.springer.com/content/pdf/10.1007/s40273-023-01268-5.pdf

Reference114 articles.

1. International Diabetes Federation. IDF Diabetes Atlas 2021, Tenth edition. 2021

2. Hex N, Bartlett C, Wright D, et al. Estimating the current and future costs of Type 1 and Type 2 diabetes in the UK, including direct health costs and indirect societal and productivity costs: estimating current and future costs of Type 1 and Type 2 diabetes in the UK. Diabet Med. 2012;29(7):855–62. https://doi.org/10.1111/j.1464-5491.2012.03698.x.

3. Cannon A, Handelsman Y, Heile M, et al. Burden of illness in type 2 diabetes mellitus. JMCP 2018; 24 (9): S5–S13. https://doi.org/10.18553/jmcp.2018.24.9-a.s5

4. Janssen LMM, Hiligsmann MJC, Elissen AMJ, et al. Burden of disease of type 2 diabetes mellitus: cost of illness and quality of life estimated using the Maastricht Study. Diabet Med. 2020. https://doi.org/10.1111/dme.14285.

5. Herman WH, Braffett BH, Kuo S, et al. What are the clinical, quality-of-life, and cost consequences of 30 years of excellent vs poor glycemic control in type 1 diabetes? J Diabetes Complicat. 2018;32(10):911–5. https://doi.org/10.1016/j.jdiacomp.2018.05.007.

Cited by 3 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Underuse of GLP-1 receptor agonists in the management of type 2 diabetes despite a favorable benefit-safety profile;Expert Opinion on Drug Safety;2024-05-13

2. Cost consequence analysis of adding semaglutide to treatment regimen for patients with Type II diabetes in Saudi Arabia;Saudi Pharmaceutical Journal;2024-05

3. O-Linked N-Acetylglucosamine Transferase Regulates Bone Homeostasis Through Alkaline Phosphatase Pathway in Diabetic Periodontitis;Molecular Biotechnology;2023-11-11